Company Description
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.
It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease.
In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi.
The company was incorporated in 1989 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 1989 |
| IPO Date | May 17, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,402 |
| CEO | Brett Monia |
Contact Details
Address: 2855 Gazelle Court Carlsbad, California 92010 United States | |
| Phone | 760 931 9200 |
| Website | ionis.com |
Stock Details
| Ticker Symbol | IONS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874015 |
| CUSIP Number | 462222100 |
| ISIN Number | US4622221004 |
| Employer ID | 33-0336973 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, Chief Executive Officer and Director |
| Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive Vice President of Finance and Chief Financial Officer |
| Patrick R. O'Neil Esq. | Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary |
| Kyle Jenne | Executive Vice President and Chief Global Product Strategy Officer |
| Dr. Richard S. Geary Ph.D. | Strategic Consultant |
| Dr. Holly Kordasiewicz Ph.D. | Executive Vice President and Chief Development Officer |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President of Research |
| Charles G. Asare M.D., M.P.H. | Vice President and Head of Drug Safety |
| Brian Birchler | Executive Vice President of Corporate and Development Operations |
| Dr. Sotirios Tsimikas M.D. | Senior Vice President of Global Cardiovascular Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | 144 | Filing |
| Feb 11, 2026 | 144 | Filing |
| Feb 6, 2026 | 144 | Filing |
| Feb 2, 2026 | 144 | Filing |
| Jan 30, 2026 | 144 | Filing |
| Jan 30, 2026 | 144 | Filing |
| Jan 30, 2026 | 144 | Filing |